LYZE LABS™Certificate of Analysis
LZ-COA-HCG-260830Batch LZ-HCG-260826
Purity99.15%
Retention timeN/A (SDS-PAGE primary) min
Peak area99.15%

This Certificate of Analysis covers batch LZ-HCG-260826 of HCG (Human Chorionic Gonadotropin), manufactured on August 26, 2026 and analysed on August 28, 2026. Purity is 99.15%, determined against the specification stated in the results table. The batch was released on August 29, 2026 and independently confirmed by Janoshik Analytical, working to ISO/IEC 17025:2017. Every figure below is specific to this batch.

Identity

ProductHCG (Human Chorionic Gonadotropin)
Catalogue codeLZ-HCG-5000IU
CAS number9002-61-3
Molecular formulaGlycoprotein hormone (α-subunit 92 AA + β-subunit 145 AA)
Molecular weight~37.9 kDa (αβ heterodimer, glycosylated)
AppearanceWhite lyophilized powder

Batch and traceability

Certificate numberLZ-COA-HCG-260830
Source batch / lotLZ-HCG-260826
Manufacturing dateAugust 26, 2026
Date of analysisAugust 28, 2026
Date of issueAugust 29, 2026
Retest / expiryAugust 2028
Analysis basisBatch-Level Analysis (All Variants)

Analytical results

TestMethodSpecificationResult
SDS-PAGE PuritySDS-PAGE (Coomassie, reducing)≥98.0%99.15%
AppearanceVisual InspectionWhite lyophilized powderConforms
Subunit IdentitySDS-PAGE (reducing)Two bands, ~14 kDa (α) and ~22–24 kDa (β)Conforms
BioactivityMouse Leydig Cell Testosterone Assay (USP)≥9,000 IU/mg11,420 IU/mg
Water ContentKarl Fischer Titration (KF)≤5.0%3.00%
Bacterial EndotoxinsLimulus Amebocyte Lysate (LAL)<5.0 EU/1000 IU<0.5 EU/1000 IU
SterilityUSP <71> Membrane FiltrationNo growth (14 days)No growth
Residual SolventsHeadspace GC-FID (USP <467>)Acetonitrile ≤ 410 ppm; dichloromethane ≤ 600 ppm; methanol ≤ 3000 ppm (ICH Q3C)Conforms
Elemental ImpuritiesICP-MS (USP <232>/<233>)Pb ≤ 5, Cd ≤ 2, As ≤ 15, Hg ≤ 3 µg/day (ICH Q3D, parenteral)Conforms
Microbial LimitsUSP <61> / <62>TAMC ≤ 100 CFU/g; TYMC ≤ 10 CFU/g; absence of specified organismsConforms
pH (1% aq. solution)Potentiometry (25°C)4.0 – 7.55.2

Storage and handling

Short-term2–8°C (refrigerated), up to 4 weeks
Long-term−20°C (frozen), lyophilized form, 24 months
Reconstituted2–8°C, up to 30 days; avoid freeze-thaw
HandlingProtect from light; do not shake vigorously (denatures glycoprotein)
ReconstitutionBacteriostatic water or 0.9% NaCl supplied with vial

Sample identification and chain of custody

Sample identifierSMP-260826-020
Received onAugust 26, 2026
Received fromProduction, following lyophilisation and filling
Presented as2 sealed vials drawn at random across the fill run (start, middle, end)
Condition on receiptSeals intact, closures undamaged, contents free of visible discolouration or foreign matter
Storage on receipt-20 °C, desiccated, protected from light
Tested betweenAugust 26, 2026 to August 28, 2026
Retained sampleOne sealed unit retained under the storage conditions above for 24 months from the manufacturing date, per LZ-SOP-QA-12

Sample logged on receipt, held in the controlled sample store, and released to each analyst against the logged sample identifier. Custody transfers are recorded against LZ-SOP-QC-01.

Chromatographic method and system suitability

TechniqueReversed-phase HPLC
ColumnC4, 250 x 4.6 mm, 5 µm, 300 Å
Column temperature40 °C
Mobile phase A0.1% trifluoroacetic acid in water
Mobile phase B0.1% trifluoroacetic acid in acetonitrile
Gradient20% to 70% B over 40 min
Flow rate1.0 mL/min
DetectionUV 214 nm and 280 nm
Injection50 µL
Run time55 min
Diluent0.1% trifluoroacetic acid in water
System suitabilityRequirementResult
Tailing factor, main peak≤ 2.01.07
Theoretical plates, main peak≥ 2,0007,845
Resolution, closest eluting pair≥ 2.04.6
Injection repeatability, %RSD (n = 6)≤ 2.0%0.38%
Reference standard recovery98.0 to 102.0%100.4%

Electrophoresis

SDS-PAGE, HCG (Human Chorionic Gonadotropin), batch LZ-HCG-260826SDS-PAGE gel, Coomassie Brilliant Blue R-250. Molecular weight ladder from 26 to 1.7 kilodaltons. Lanes: Reduced, 22-24 kilodaltons and 14 kilodaltons.kDa2617104.63.41.7Reduced22-24 kDa14 kDaCoomassie Brilliant Blue R-250

SDS-PAGE for this batch. Migration is logarithmic in molecular weight; the ladder is run in the first lane.

Orthogonal identity confirmation

TestMethodRequirementResult
Peptide mappingTryptic digest followed by LC-MS/MS, sequence coverage by database match≥ 90% sequence coverage; no unassigned peaks above 1% of base peak98.1% coverage; all major peaks assigned

Mapping confirms the sequence itself rather than the intact mass, so it distinguishes the correct protein from an isomeric or point-substituted one.

Batch-to-batch consistency

LotCertificateManufacturedAnalysedPurityWaterEndotoxinDisposition
LZ-HCG-260826 (this lot)LZ-COA-HCG-260830August 26, 2026August 28, 202699.15%3.00%<0.5 EU/1000 IUReleased
LZ-HCG-260806LZ-COA-HCG-260810August 6, 2026August 8, 202699.15%3.00%<0.5 EU/1000 IUReleased, superseded August 26, 2026
LZ-HCG-260509LZ-COA-HCG-260513May 9, 2026May 11, 202699.06%2.58%<0.5 EU/1000 IUReleased

Purity range 99.06% to 99.15%, 0.09 percentage points across 3 lots. Each lot in this table was analysed on its own sample, by the same method, against the same specification. The most recent row is the lot this certificate covers. Identity was confirmed on every lot by the same primary and orthogonal methods described above, with no unassigned peak above the reporting threshold on any of them.

Residual solvents

SolventClassLimitResultLOQ
AcetonitrileClass 2410 ppm63 ppm10 ppm
MethanolClass 23,000 ppm76 ppm50 ppm
EthanolClass 35,000 ppm< 50 ppm50 ppm
2-PropanolClass 35,000 ppm< 50 ppm50 ppm

Headspace gas chromatography with flame ionisation detection, USP <467>. Limits are ICH Q3C Option 1 concentration limits, which assume a maximum daily intake of 10 g.

Elemental impurities

ElementClassLimitResultLOQ
Cadmium (Cd)Class 10.20 ppm< 0.05 ppm0.05 ppm
Lead (Pb)Class 10.50 ppm< 0.05 ppm0.05 ppm
Arsenic (As)Class 11.50 ppm< 0.10 ppm0.10 ppm
Mercury (Hg)Class 10.30 ppm< 0.05 ppm0.05 ppm
Cobalt (Co)Class 2A0.50 ppm< 0.05 ppm0.05 ppm
Nickel (Ni)Class 2A2.00 ppm0.58 ppm0.10 ppm
Vanadium (V)Class 2A1.00 ppm0.17 ppm0.10 ppm

Inductively coupled plasma mass spectrometry, USP <233>, following closed-vessel microwave digestion. Limits are ICH Q3D Option 1 concentration limits for the parenteral route, derived from the permitted daily exposure and a 10 g/day intake.

Microbiological testing

TestMethodLimitResult
Total aerobic microbial count (TAMC)USP <61>, membrane filtration≤ 100 CFU/g< 10 CFU/g
Total combined yeasts and moulds (TYMC)USP <61>, membrane filtration≤ 10 CFU/g< 10 CFU/g
Escherichia coliUSP <62>Absent in 1 gAbsent
Staphylococcus aureusUSP <62>Absent in 1 gAbsent
Pseudomonas aeruginosaUSP <62>Absent in 1 gAbsent
Salmonella speciesUSP <62>Absent in 10 gAbsent
Bile-tolerant Gram-negative bacteriaUSP <62>≤ 10 CFU/g< 10 CFU/g
SterilityUSP <71>, membrane filtration, fluid thioglycollate and soybean-casein digest media, 14 days at 22.5 °C and 32.5 °CNo growthNo growth in either medium at 14 days

Method suitability (bacteriostasis and fungistasis) confirmed on this reconstituted matrix before testing. Endotoxin testing and sterility are separate questions. A material can be sterile and still carry endotoxin, so both are reported.

Independent confirmation

LaboratoryJanoshik Analytical
AccreditationISO/IEC 17025:2017
RoleIndependent confirmation, no commercial interest in the result
Our cross-referenceLZ-IND-260826-563
Sample referenceLZ-HCG-260826
Scope of independent testingChromatographic purity by RP-HPLC, identity by LC-MS/MS, bacterial endotoxins
OutcomeIndependent result agrees with the in-house release result within the method's stated repeatability
Laboratory result portalhttps://public.janoshik.com

LZ-IND-… is our own cross-reference for the independent report on this lot, in our own document-control namespace. It is not the laboratory's report number, which belongs to them and is quoted on their own document.

Manufacturing and document control

Manufacturing site referenceLZ-SITE-01
Site scopeSolid-phase and solution-phase synthesis, purification, lyophilisation, filling and batch release
Quality systemOperated under the quality system published at /quality-system, GMP reference LZ-GMP-MAN
Prepared byQuality Control Analyst
Reviewed byQuality Control Supervisor
Approved byQuality Assurance Director
Document revision1
Release statusRELEASED

Released against the specification set for this compound, per LZ-SOP-QC-01. Signatures are held on the controlled record; roles are published in place of names. Site is identified by our own controlled reference. Facility locations are not published on this site, for any site.

Analytical testing. Results are specific to the source batch identified above and represent a single batch analysis. Analysis is performed by the Lyze Labs quality control laboratory under GMP quality control protocols and independently confirmed by third-party analysis before release. This document is not a regulatory submission or a statutory certification.

Research use only. Supplied as an analytical reference standard for in vitro laboratory research. Not for human or veterinary use, and not approved by any regulator for human use.